Report : Europe Kidney Disease Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Diagnosis and Treatment); End User (Hospitals, Diagnostic Laboratories, and Others); and Country
Diagnosis Segment Held Largest Share of Product in Europe Kidney Disease Market in 2019
According to The Insight Partners market research study of ‘Europe Kidney Disease Market Forecast to 2027 - COVID-19 Impact and Analysis by product, and end-user’ the Europe kidney disease market is expected to reach US$ 37.311.1 million in 2027 from US$ 23,121.5 in 2019. The market is estimated to grow with a CAGR of 6.2% from 2020-2027. The report provides trends prevailing in the Europe kidney disease market and the factors driving market along with those that act as hindrances.
Based on the product, the Europe the kidney disease market, is segmented into diagnosis and treatment. The diagnosis segment held the largest share of the market in 2019, also the same segment is anticipated to register the highest CAGR in the market during the forecast period. The Chronic kidney disease (CKD) can be diagnosed with blood and urine tests. Diagnosis of kidney disease is made with various tests such as blood tests, urine tests, imaging tests, and others. The tests must be performed in conditions such as diabetes, high blood pressure, heart disease, and a family history of kidney failure. Early kidney disease usually doesn’t have any symptoms. Testing is the only way to know how well kidneys are working.
The growth of this market is estimated to grow owing to key driving factors such as increasing incidences of chronic kidney diseases and growth in government expenditure in the healthcare sector. However, the market is expected experiencing slow growth during the forecast period owing to lack of awareness of kidney diseases.
Abbott, GlaxoSmithKline plc, and F. Hoffmann-La Roche Ltd are among the leading companies operating in the Europe kidney disease market.
The report segments Europe Kidney Disease Market as Follows: